Barclays Maintains Overweight on Twist Bioscience, Raises Price Target to $60
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Luke Sergott maintains an Overweight rating on Twist Bioscience (NASDAQ:TWST) and raises the price target from $45 to $60.
June 28, 2024 | 4:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays analyst Luke Sergott has maintained an Overweight rating on Twist Bioscience and raised the price target from $45 to $60.
The increase in the price target from $45 to $60 by a reputable analyst at Barclays is a positive signal for investors, indicating confidence in the company's future performance. This is likely to result in a short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100